Bharat Biotech’s Nucelion partners with VeGen Bio for cell therapy innovation

Metro India News | Hyderabad 

Hyderabad based Nucelion Therapeutics Pvt. Ltd. (“Nucelion”), a subsidiary of Bharat Biotech, a specialized cell and gene therapy contract research, development, and manufacturing organization (CRDMO);  and VeGen Bio Pvt. Ltd. (“VeGen Bio” / “VeGen Labs”), a Hyderabad-based precision oncology company, announced on Wednesday a strategic collaboration for the technology transfer, clinical manufacturing, and commercial production of innovative cell therapies in India.

Nucelion will serve as the technology transfer and clinical- and commercial-stage manufacturing partner for VeGen Bio's lead candidate, VL-2511, a first-in-class dual BCMA/CD19 autologous CAR-T therapy for multiple myeloma. The collaboration centres on therapeutic translation, process development and manufacturing scale-up, rather than marketing or distribution.  Raghu Malapaka, Chief Business Officer of Nucelion Therapeutics Pvt. Ltd mentioned that the company’s work on VeGen’s dual-target CAR-T program shows that model in action and builds the capacity India needs to bring these therapies to more patients.

Prashant Bhavar, Director, VeGen Bio Pvt. Ltd said that VL-2511 is a key program in VeGen Bio’s mission to advance innovative therapies for unmet medical needs and added that the partnership provides VeGen Bio with a pathway to technology transfer, manufacturing, and pipeline expansion. The collaboration is built upon a complementary business structure tailored to align scientific ambition, manufacturing excellence, and long-term commercial viability.